Melphalan Aqvida

Melphalan, the active ingredient in Melphalan Aqvida, is an alkylating agent presented as an intravenous solution for chemotherapy use. It is employed in the treatment of certain hematologic and solid tumours, particularly in patients with multiple myeloma, ovarian cancer or malignant melanoma. GNH USA supplies Melphalan Aqvida as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melphalan Aqvida belongs to the alkylating antineoplastic class and is used in cancers that are responsive to DNA‑cross‑linking therapy.

Multiple myeloma: helps achieve disease control by reducing malignant plasma cell proliferation. Ovarian cancer: contributes to tumour shrinkage and prolongs progression‑free survival when combined with other agents. Malignant melanoma: provides cytotoxic activity against melanoma cells resistant to other chemotherapies.

Melphalan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring shortly after infusion. - Alopecia: reversible hair loss affecting scalp and body hair. - Myelosuppression: decreased white blood cells, red cells and platelets. - Fatigue: generalized tiredness that may persist for days.

Serious or Rare Side Effects: - Severe infection: due to profound neutropenia. - Secondary malignancies: rare development of new cancers after treatment. - Pulmonary toxicity: interstitial pneumonitis or fibrosis in rare cases.

When using Melphalan, clinicians should observe several safety measures.

Monitor blood counts: perform regular CBC to detect myelosuppression. Assess renal function: adjust therapy if creatinine clearance is reduced. Avoid in hypersensitivity: discontinue if allergic reactions occur. Contraception advised: patients of child‑bearing potential should use effective birth control. Dose adjustment in hepatic impairment: consider reduced dosing for liver dysfunction. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan can interact with other medicines, influencing its safety and efficacy.

Major Interactions (Avoid): - Concurrent alkylating agents: additive myelosuppression and organ toxicity. - Radiotherapy combined with melphalan: heightened tissue damage and delayed healing.

Moderate Interactions (Monitor Closely): - Azathioprine: increased risk of bone‑marrow suppression. - Live vaccines: potential for uncontrolled infection due to immunosuppression. - CYP450 inhibitors: may raise melphalan plasma levels, requiring closer monitoring.